Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 8INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Uveal Melanoma 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Hyperthermia 1Eye Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NIH × Laparotomy × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT00062933 2012-08-20

A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
40 enrolled
Dermatologic

Hyperthermia, Uveal Melanoma, Eye Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡